Status:
COMPLETED
Phosphodiesterase-5-inhibitors for Right Heart Failure After Left Ventricular Assist Device Implantation
Lead Sponsor:
University Hospital, Essen
Conditions:
Phosphodiesterase Inhibitor Adverse Reaction
Right-Sided Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Refractory right heart failure is common during the postoperative period after left ventricular assist device implantation. Oral phosphodiesterase-5 inhibitors are oft initiated in order to facilitate...
Detailed Description
The study aims to assess clinical and echocardiographic measures of right ventricular function before and after discontinuation of the oral phosphodiesterase-5 inhibitor in patients on left ventricula...
Eligibility Criteria
Inclusion
- Age \>18 y.o.
- clinically stable, ambulatory heart failure patients on left ventricular assist device support
- implantation \> 1 month before inclusion in the study
- uninterrupted therapy with an oral phosphodiesterase-5 inhibitor initiated during the early postoperativ period due to right heart failure
Exclusion
- unable to provide written informed consent
- refusal to provide written informed consent
Key Trial Info
Start Date :
October 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2021
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04117659
Start Date
October 15 2019
End Date
March 15 2021
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45122